2021
1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durhman J, Liden S, Miles T, Lopez-Vidal T, Leatherman J, Sharma A, Ahuja N, Weekes C, O'Dwyer P, Monga D, Binder K, Azad N. 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals Of Oncology 2021, 32: s1087-s1088. DOI: 10.1016/j.annonc.2021.08.797.Peer-Reviewed Original Research
2016
Predictors of improved survival for patients with retroperitoneal sarcoma
Giuliano K, Nagarajan N, Canner JK, Wolfgang CL, Bivalacqua T, Terezakis S, Herman J, Schneider EB, Ahuja N. Predictors of improved survival for patients with retroperitoneal sarcoma. Surgery 2016, 160: 1628-1635. PMID: 27495850, DOI: 10.1016/j.surg.2016.05.041.Peer-Reviewed Original ResearchConceptsRetroperitoneal sarcomaMultivariable survival analysisSurvival analysisRetroperitoneal sarcoma patientsEnd Results (SEER) databaseOperative resectionImproved survivalLymph nodesSurvival benefitDistant metastasisHistologic typeResults databaseSarcoma patientsRare tumorCancer DatabaseLonger survivalPatientsSarcomaSurvivalParametric survival functionsLocal extensionFurther studiesHigh rateResectionRecurrenceIGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers
Fu T, Pappou EP, Guzzetta AA, de Freitas Calmon M, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N. IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. Annals Of Surgery 2016, 263: 337-344. PMID: 25822686, PMCID: PMC4648704, DOI: 10.1097/sla.0000000000001204.Peer-Reviewed Original ResearchConceptsStage II colorectal cancerRisk of recurrenceIGFBP-3 methylationLymph nodesColorectal cancerHazard ratioPrimary tumorHigh riskIndependent cohortFive-year recurrence-free survival ratesRecurrence-free survival ratesHigh-risk patientsSignificant prognostic factorsIdentification of patientsProportional hazards modelIGFBP-3Prognostic factorsTumor characteristicsPredicts RecurrenceHazards modelPatientsRecurrenceSurvival rateMultivariate analysisSurgery
2015
A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.
Reiss K, Ahuja N, Baylin S, Mauro L, Linden S, White S, Laheru D, Herman J, Wolfgang C, Weiss M, Cameron J, Makary M, Azad N. A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence. Journal Of Clinical Oncology 2015, 33: tps4144-tps4144. DOI: 10.1200/jco.2015.33.15_suppl.tps4144.Peer-Reviewed Original Research
2014
A Systematic Review of Solid-Pseudopapillary Neoplasms
Law JK, Ahmed A, Singh VK, Akshintala VS, Olson MT, Raman SP, Ali SZ, Fishman EK, Kamel I, Canto MI, Dal Molin M, Moran RA, Khashab MA, Ahuja N, Goggins M, Hruban RH, Wolfgang CL, Lennon AM. A Systematic Review of Solid-Pseudopapillary Neoplasms. Pancreas 2014, 43: 331-337. PMID: 24622060, PMCID: PMC4888067, DOI: 10.1097/mpa.0000000000000061.Peer-Reviewed Original ResearchConceptsSolid pseudopapillary neoplasmSystematic reviewExcellent long-term prognosisDisease-free survivalMainstay of treatmentMean tumor sizeLong-term prognosisAbdominal painNonspecific symptomsPancreatic resectionMedian timeCommon symptomsNeoplasm casesTumor sizeMean agePatientsNumber of casesYoung womenRecurrenceNeoplasmsSymptomsMonthsTotalPainResection
2008
Management of Retroperitoneal Sarcomas
Hueman MT, Herman JM, Ahuja N. Management of Retroperitoneal Sarcomas. Surgical Clinics Of North America 2008, 88: 583-597. PMID: 18514700, DOI: 10.1016/j.suc.2008.03.002.Peer-Reviewed Original ResearchConceptsRetroperitoneal sarcomaLocal recurrenceMorbidity of therapyDistant metastatic diseaseAggressive surgical approachCurative treatment optionManagement of patientsHigh-grade lesionsMetastatic diseaseSurgical therapyTherapeutic challengeSurgical approachTreatment optionsExtent of invasionDisease controlSarcomaCommon typePatientsRecurrenceTherapyMorbidityLesionsManagementDiseaseDiagnosis